SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Joshua J. Lander, Matthew F. Moran, Does positive pressure body weight-support alter spatiotemporal gait parameters in healthy and parkinsonian individuals?, NeuroRehabilitation, 2017, 40, 2, 271

    CrossRef

  2. 2
    Jeanne C Latourelle, Michael T Beste, Tiffany C Hadzi, Robert E Miller, Jacob N Oppenheim, Matthew P Valko, Diane M Wuest, Bruce W Church, Iya G Khalil, Boris Hayete, Charles S Venuto, Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation, The Lancet Neurology, 2017, 16, 11, 908

    CrossRef

  3. 3
    Filipe B Rodrigues, Joaquim J Ferreira, Opicapone for the treatment of Parkinson’s disease, Expert Opinion on Pharmacotherapy, 2017, 18, 4, 445

    CrossRef

  4. 4
    Rohit Dhall, David L. Kreitzman, Advances in levodopa therapy for Parkinson disease, Neurology, 2016, 86, 14 Supplement 1, S13

    CrossRef

  5. 5
    C. Laurencin, T. Danaila, E. Broussolle, S. Thobois, Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited, Revue Neurologique, 2016, 172, 8-9, 512

    CrossRef

  6. 6
    Jong-Suep Baek, Chee Chong Choo, Cheng Qian, Nguan Soon Tan, Zexiang Shen, Say Chye Joachim Loo, Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease, Small, 2016, 12, 27
  7. 7
    Thomas Müller, Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease, Drugs, 2015, 75, 2, 157

    CrossRef

  8. 8
    Oscar S. Gershanik, Improving l-dopa therapy: The development of enzyme inhibitors, Movement Disorders, 2015, 30, 1
  9. 9
    Philippe Huot, L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?, Journal of the Neurological Sciences, 2015, 351, 1-2, 9

    CrossRef

  10. 10
    Livia Dézsi, László Vécsei, Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 3, 409

    CrossRef

  11. 11
    David Devos, Stéphanie Lejeune, Florence Cormier-Dequaire, Khadija Tahiri, Fanny Charbonnier-Beaupel, Nathalie Rouaix, Alain Duhamel, Bernard Sablonnière, Anne-Marie Bonnet, Cecilia Bonnet, Noel Zahr, Jean Costentin, Marie Vidailhet, Jean-Christophe Corvol, Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 2, 170

    CrossRef

  12. 12
    Eduardo Tolosa, Basilio Hernández, Gurutz Linazasoro, Juan José López-Lozano, Pablo Mir, José Marey, Jaime Kulisevsky, Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial, Journal of Neural Transmission, 2014, 121, 4, 357

    CrossRef

  13. 13
    Siegfried Muhlack, Lennard Herrmann, Stephan Salmen, Thomas Müller, Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition, Journal of Neural Transmission, 2014, 121, 11, 1357

    CrossRef

  14. 14
    Rajesh Pahwa, Kelly E. Lyons, Robert A. Hauser, Stanley Fahn, Joseph Jankovic, Emmanuelle Pourcher, Ann Hsu, Martin O'Connell, Sherron Kell, Suneel Gupta, Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, 2, 142

    CrossRef

  15. 15
    Livia Dézsi, László Vécsei, Safinamide for the treatment of Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 5, 729

    CrossRef

  16. 16
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  17. 17
    Rajesh Pahwa, Kelly E. Lyons, Treatment of early Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 442

    CrossRef

  18. 18
    Qing Lv, Baorong Zhang, Application of the concept of continuous dopaminergic stimulation for the management of Parkinson’s disease, Neuroscience Bulletin, 2013, 29, 5, 661

    CrossRef

  19. 19
    Nin Bajaj, Robert A Hauser, Igor D Grachev, Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes, Journal of Neurology, Neurosurgery & Psychiatry, 2013, 84, 11, 1288

    CrossRef

  20. 20
    S. Asayama, R. Wate, S. Kaneko, T. Asayama, M. Oki, A. Tsuge, M. Nagashima, J. Morita, S. Nakamura, M. Nakamura, M. Nishii, K. Fujita, A. Saito, S. Nakano, H. Ito, H. Kusaka, Levodopa challenge test and 123I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease, Acta Neurologica Scandinavica, 2013, 128, 3
  21. 21
    K. Ray Chaudhuri, Alexandra Rizos, Kapil D. Sethi, Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, 2013, 120, 9, 1305

    CrossRef

  22. 22
    Santiago Perez-Lloret, María Verónica Rey, Pietro Lucca Ratti, Olivier Rascol, Rotigotine transdermal patch for the treatment of Parkinson’s Disease, Fundamental & Clinical Pharmacology, 2013, 27, 1
  23. You have free access to this content23
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  24. 24
    Li Zuo, Michael S. Motherwell, The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease, Gene, 2013, 532, 1, 18

    CrossRef

  25. 25
    Philippe Huot, Tom H. Johnston, Tessa Snoeren, James B. Koprich, Michael P. Hill, Susan H. Fox, Jonathan M. Brotchie, Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque, European Journal of Neuroscience, 2013, 37, 5
  26. 26
    Ronald F. Pfeiffer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  27. 27
    Ronald Pfeiffer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  28. 28
    Robert A. Hauser, Donald G. Grosset, [123I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes, Journal of Neuroimaging, 2012, 22, 3
  29. 29
    Sandro Zambito Marsala, Manuela Gioulis, Roberto Ceravolo, Michele Tinazzi, A Systematic Review of Catechol-O-Methyltransferase Inhibitors, Clinical Neuropharmacology, 2012, 35, 4, 185

    CrossRef

  30. 30
    Jordan J. Elm, Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study–1, Movement Disorders, 2012, 27, 12
  31. 31
    Thomas Müller, Drug therapy in patients with Parkinson’s disease, Translational Neurodegeneration, 2012, 1, 1, 10

    CrossRef

  32. 32
    Nilton F. Frazão, Eudenilson L. Albuquerque, Umberto L. Fulco, David L. Azevedo, Glaydson L. F. Mendonça, Pedro Lima-Neto, Ewerton W. S. Caetano, Josias V. Santana, Valder N. Freire, Four-level levodopa adsorption on C60 fullerene for transdermal and oral administration: a computational study, RSC Advances, 2012, 2, 22, 8306

    CrossRef

  33. 33
    Heinz Reichmann, Murat Emre, Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson’s disease: focus on levodopa/carbidopa/entacapone, Expert Review of Neurotherapeutics, 2012, 12, 2, 119

    CrossRef

  34. 34
    Monica Colamartino, Luca Padua, Tommaso Cornetta, Antonella Testa, Renata Cozzi, Recent advances in pharmacological therapy of Parkinson’s disease: Levodopa and carbidopa protective effects against DNA oxidative damage, Health, 2012, 04, 11, 1191

    CrossRef

  35. 35
    R. Iansek, M. Danoudis, A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson’s disease, Parkinsonism & Related Disorders, 2011, 17, 7, 533

    CrossRef

  36. 36
    Claire Henchcliffe, Richard Dodel, M. Flint Beal, Biomarkers of Parkinson's disease and Dementia with Lewy bodies, Progress in Neurobiology, 2011, 95, 4, 601

    CrossRef

  37. 37
    Kelly E. Lyons, Rajesh Pahwa, Diagnosis and Initiation of Treatment in Parkinson's Disease, International Journal of Neuroscience, 2011, 121, sup2, 27

    CrossRef

  38. 38
    D. Salat-Foix, C. N. Andrews, J. Meddings, O. Suchowersky, Gastrointestinal Symptoms in Parkinson Disease: Clinical Aspects and Management, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2011, 38, 04, 557

    CrossRef

  39. 39
    Carrie Brienne Hurelbrink, Simon John Geoffrey Lewis, Pathological considerations in the treatment of Parkinson's disease: More than just a wiring diagram, Clinical Neurology and Neurosurgery, 2011, 113, 1, 1

    CrossRef

  40. 40
    Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz, Cristina Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease, Movement Disorders, 2011, 26, S3
  41. 41
    Tom H. Johnston, Emma L. Lane, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  42. 42
    Juan Carlos Gómez Esteban, Neurofarmacología Contemporánea, 2011,

    CrossRef

  43. 43
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  44. 44
    Jarosław Sławek, Andrzej Bogucki, Dojelitowa postać lewodopy w leczeniu zaawansowanej choroby Parkinsona, Neurologia i Neurochirurgia Polska, 2010, 44, 4, 396

    CrossRef

  45. 45
    Thomas Müller, Entacapone, Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 8, 983

    CrossRef

  46. 46
    Fabrizio Stocchi, Stefano Marconi, Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease, Clinical Neuropharmacology, 2010, 33, 4, 198

    CrossRef

  47. You have free access to this content47
    S. Tsouli, S. Konitsiotis, How should we treat a patient with early Parkinson’s disease?, International Journal of Clinical Practice, 2010, 64, 9
  48. 48
    Fabrizio Stocchi, Olivier Rascol, Karl Kieburtz, Werner Poewe, Joseph Jankovic, Eduardo Tolosa, Paulo Barone, Anthony E. Lang, C. Warren Olanow, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study, Annals of Neurology, 2010, 68, 1
  49. 49
    Robert A. Hauser, Kelly E. Lyons, Reply: Intravenous glutathione in Parkinson's disease, Movement Disorders, 2010, 25, 7
  50. 50
    J. Eric Ahlskog, Seniors with Parkinson's Disease: Initial Medical Treatment, Journal of Clinical Neurology, 2010, 6, 4, 159

    CrossRef

  51. 51
    Thomas Müller, The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease, Clinical Medicine Insights: Therapeutics, 2010, 2, CMT.S1169

    CrossRef

  52. 52
    Kapil D. Sethi, The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease, The Neurologist, 2010, 16, 2, 76

    CrossRef

  53. 53
    John Y. Fang, UPDATE ON THE MEDICAL MANAGEMENT OF PARKINSON DISEASE, CONTINUUM: Lifelong Learning in Neurology, 2010, 16, 96

    CrossRef

  54. 54
    Seppo Kaakkola, Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors, 2010,

    CrossRef

  55. 55
    E.V. Encarnacion, R.A. Hauser, Encyclopedia of Movement Disorders, 2010,

    CrossRef

  56. 56
    Livia Dézsi, László Vécsei, Established therapies and novel targets in the treatment of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2009, 2, 6, 631

    CrossRef

  57. 57
    Lauren C Seeberger, Robert A Hauser, Levodopa/carbidopa/entacapone in Parkinson’s disease, Expert Review of Neurotherapeutics, 2009, 9, 7, 929

    CrossRef

  58. 58
    Stuart H. Isaacson, Robert A. Hauser, Review: Improving symptom control in early Parkinson’s disease, Therapeutic Advances in Neurological Disorders, 2009, 2, 6, 393

    CrossRef

  59. 59
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,
  60. 60
    Nicholas D. Child, Bryan T. Klassen, Evidence-based treatment of Parkinson's disease,